Its lead candidate Tune-401, which aims to repress viral DNA that contributes to infection, has entered into clinical trials in New Zealand and Hong Kong.
With new treatments in neurology, and more in development in cardiology and autoimmune diseases, precision medicine is moving ...
In OurHealth Study, Researchers Seek Genetic Underpinnings of Cardiovascular Disease in South Asians
Researchers from the Broad Institute, Mass General, Stanford, and elsewhere are investigating why patients with South Asian ...
The firm, which plans to use the ticker symbol "MAZE" on the Nasdaq, develops drugs designed to mimic the protective effects ...
The firms will work together to create a bispecific antibody with two anti-cancer payloads and evaluate its therapeutic potential.
The firm is expanding its melanoma portfolio while launching new trials of T-cell receptor therapies in oncology, infectious disease, and autoimmune disease.
A new study found that fewer African and Asian patients had clinically actionable alterations for lung, breast, and colorectal cancer.
The firm will pause development of lunresertib and camonsertib while focusing on development of two newer programs.
Platforms using natural language processing are showing promise in scanning patients' records for biomarkers and other enrollment criteria for clinical trials.
NEW YORK – RheumaGen, a new company developing cell and gene therapies for autoimmune diseases, launched on Thursday with $15 million in Series A funding. The Series A funding round was led by SPRIM ...
NEW YORK – MOMA Therapeutics on Wednesday said it added the next-generation PARP1 inhibitor MOMA-989 to its pipeline of drug candidates and anticipates filing an investigational new drug application ...
These moves will enable the gene-editing company to focus resources on late-stage programs as it aims to launch a commercial product by 2027, it said.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback